Clinical trial
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid…
NCT00101296 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00101296 |
|---|---|
| Title | Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Official title | Phase I Trial of R115777 (NSC 702818) in Relapsed, Refractory or High Risk Myeloid Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities and 12 more |
| Intervention type | Drug, Other |
| Interventions | tipifarnib, pharmacological study, laboratory biomarker analysis |
| Enrollment | 30 |
| Start date | Oct 1, 2004 |
| Primary completion | May 1, 2011 |
| First posted | Jan 10, 2005 |
| Last update posted | Feb 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: